Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Aspirin but not other NSAID drugs may help prevent cancer of the pancreas

Aspirin might be chemoprotective for pancreatic cancer claims a report in the Journal of the National Cancer Institute.

News image

fiogf49gjkf04

Aspirin is already known to reduce the risk of colon cancer, and laboratory studies have indicated that non-steroidal anti-inflammatory drugs (NSAIDs) may inhibit pancreatic cancer. Until now, however, epidemiological data to support this finding has been limited.

Now a prospective study conducted between 1992 and 1999, by members of the Division of Epidemiology at the University of Minnesota in Minneapolis, USA, has shed light on this topic, suggesting that aspirin may indeed prevent cancer of the pancreas.

Dr Kristin E. Anderson and colleagues assessed data on 28,283 women, aged 55 to 69, with the aim of examining the association between self-reported use of aspirin and other NSAIDs and the incidence of pancreatic cancer.

A total of 80 incident cases of pancreatic cancer were identified during 7 years of follow-up.

Following analysis of the data, the risk of pancreatic cancer was found to be 43% lower in women who took aspirin, or aspirin-containing products, compared to those women who did not.

There was a trend of decreasing risk of pancreatic cancer incidence with increasing frequency of aspirin use per week.

Compared with women who never took aspirin, women who took aspirin 2 to 5 times a week had a 53% lower risk of developing the cancer, and women who took it 6 times a week had a 60% lower risk.

Non-aspirin NSAID use was not associated with incident pancreatic cancer.

The researchers suggest that these data indicate that aspirin might be chemoprotective for pancreatic cancer.

While the mechanism by which aspirin could reduce the incidence of pancreatic cancer is not clear, it is thought to involve inhibition of expression of cyclo-oxygenase, but it probably involves other mechanisms as well, say the researchers.

Risk of pancreatic cancer - 43% lower regular aspirin takers
Journal of the National Cancer Institute

"In the study, other NSAIDs, such as ibuprofen, did not decrease the incidence of pancreatic cancer, perhaps reflecting differences in their mechanism of action", said Dr Anderson.

She cautioned, however, that the researchers did not have enough evidence to rule out that other NSAIDs may also reduce the risk of pancreatic cancer.

She said that the women in the study were asked in 1992 about their use of NSAIDs, when the drugs were not as widely used and some newer types had not yet been introduced.

Writing in the current issue of the British Medical Journal, in a news article, Dr Scott Gottlieb points out that the researchers did not collect data on the dose of aspirin the participants took or on the length of time that they were taking aspirin before enrolling in the study.

He adds that they looked only at current use, which precludes a comparison of short term and long term use, and that the homogeneity of the study population - postmenopausal women, 98% of whom were white - makes it difficult to generalize the results.

J Natl Cancer Inst 2002; 94(15): 1168-1171
19 August 2002

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us